BIRMINGHAM, Ala., May 6, 2024 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will participate in the BofA Securities 2024 Health Care Conference being held in Las Vegas May 14-16, 2024.
Encompass Health's President and Chief Executive Officer Mark Tarr and Executive Vice President and Chief Financial Officer Doug Coltharp will present during a fireside chat on Tuesday, May 14, 2024, at 3 p.m. PT.
The presentation will be webcast live and available at http://investor.encompasshealth.com.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 160 hospitals in 37 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies and Modern Healthcare's Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.
Media Contact
Polly Manuel | 205 970-5912
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact
Mark Miller | 205 970-5860
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$95.27 |
| Daily Change: | 0.76 0.80 |
| Daily Volume: | 499,213 |
| Market Cap: | US$9.600B |
December 18, 2024 November 04, 2024 October 28, 2024 August 05, 2024 July 30, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
